Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2581 to 2595 of 8935 results

  1. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    Awaiting development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

    In development Reference number: GID-TA10311 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  5. Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

    In development Reference number: GID-TA10752 Expected publication date:  10 July 2026

    Technology appraisal guidance
    In development

  6. Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    Awaiting development Reference number: GID-TA11866 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  9. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-IPG10439 Expected publication date: TBC

    Interventional procedures guidance
    In development

  10. Vamikibart for treating uveitic macular oedema [ID6671]

    Awaiting development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732 ]

    In development Reference number: GID-TA11959 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]

    In development Reference number: GID-TA11958 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

    Health technology evaluations
    In development

  14. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development Reference number: GID-TA11232 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  15. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development